


How to Register for BOTOX ONE®

- Go to BOTOX ONE® homepage at www.botoxone.com
- Select the gray **Not a Member? Register** button beneath the password field OR the **Register** link in the upper right-hand corner next to the BOTOX® logo




To Set Up a BOTOX ONE® Account

Fill in the required fields

- Input email address and confirm your email. Your email address will be used as your login username and can also be used to reset your password and receive notifications
- Enter a valid password and confirm your password

Note: Password must contain at least 8 characters, 1 uppercase, 1 lowercase, 1 number, and cannot contain any part of the email address.

- Check the box to confirm registration as an account administrator (an account must have at least 1 administrator to register)
- Click the **Save and Continue** button



IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING

WARNING: DISTANT SPREAD OF TOXIN EFFECT

Postmarketing reports indicate that the effects of BOTOX® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening, and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity, but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have an underlying condition that would predispose them to these symptoms. In unapproved uses and approved indications, cases of spread of effect have been reported at doses comparable to those used to treat Cervical Dystonia and spasticity and at lower doses.

Please see Indications, Limitations of Use, and additional Important Safety Information about BOTOX® on following pages.

To Set Up a BOTOX ONE® Account (continued)

- Add in Contact Details and fill in remaining required fields including:
 - Title/Role
 - First Name
 - Last Name
 - Phone Number
- Complete the Practice Details section including all required fields (Practice Name, Place of Service, Location Name, Practice/Facility Tax ID, Street Address, City, State, ZIP Code, Phone Number)
- Complete the Preferences section including all required fields (Email and Document Delivery)
- Click the **Save and Continue** button at the bottom of the page

Note: User will be directed to the Add a Prescriber page.

Indications

Adult Bladder Dysfunction:

Overactive Bladder

BOTOX® for injection is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency in adults who have an inadequate response to or are intolerant of an anticholinergic medication.

Detrusor Overactivity Associated With a Neurologic Condition

BOTOX® is indicated for the treatment of urinary incontinence due to detrusor overactivity associated with a neurologic condition (eg, SCI, MS) in adults who have an inadequate response to or are intolerant of an anticholinergic medication.

Pediatric Detrusor Overactivity Associated With a Neurologic Condition

BOTOX® is indicated for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 5 years of age and older who have an inadequate response to or are intolerant of anticholinergic medication.

Chronic Migraine

BOTOX® is indicated for the prophylaxis of headaches in adult patients with Chronic Migraine (≥ 15 days per month with headache lasting 4 hours a day or longer).

Limitations of Use

Safety and effectiveness have not been established for the prophylaxis of episodic migraine (14 headache days or fewer per month) in 7 placebo-controlled studies.

Please see additional Indications, additional Limitations of Use, and additional Important Safety Information about BOTOX® on following pages. 2

Add a Prescriber

If you added a prescriber at the beginning of registration, review the information in the gray box.

- If you do not wish to add an additional prescriber at this time, please click **Save and Continue** after reviewing the information
- If you did not add a prescriber at the beginning of registration, you must add a new prescriber here

Add a new prescriber


- Enter a valid NPI number in the Search NPI field

Note: An NPI is 10 numeric digits. It must be an individual prescriber's NPI and not an organization's NPI.


- Click **Search**
 - Provider's name will automatically populate in the gray field based on the NPI number
- Confirm prescriber's information
- Add an Alias or Individual Tax ID if necessary

Note: The Alias field lets you add a preferred name to the prescriber other than the one returned from the NPI registry. If an alias is not entered, prescriber name will default to the name from the NPI registry.

- If you would like to add an additional prescriber, you can click the **Save and Add Additional Prescriber** button
- If you do not wish to do so now, click **Save and Continue**



The screenshot shows the 'Set Up Your BOTOX ONE Account' page. Under the 'Add New Prescriber' section, there is a text input field labeled 'Search NPI' and a blue 'Search' button. A red box highlights the search field. Below the search field are 'Back' and 'Save and Continue' buttons.



The screenshot shows the 'Set Up Your BOTOX ONE Account' page after a search. A dropdown menu is open, showing the name 'AARONSON, BARRY'. Below the dropdown, the prescriber's information is displayed: First Name: BARRY, Last Name: AARONSON, Alias: (empty), Designation: OTHER, Prescriber Specialty: Psychologist - Prescribing (Medical), NPI: 1851503787, and Individual Tax ID: (empty). At the bottom, there are 'Back', 'Save and Add Additional Prescriber', and 'Save and Continue' buttons.

Indications (continued)

Spasticity

BOTOX® is indicated for the treatment of spasticity in patients 2 years of age and older.

Limitations of Use

BOTOX® has not been shown to improve upper extremity functional abilities or range of motion at a joint affected by a fixed contracture.

Cervical Dystonia

BOTOX® is indicated for the treatment of adults with Cervical Dystonia to reduce the severity of abnormal head position and neck pain associated with Cervical Dystonia.

Blepharospasm and Strabismus

BOTOX® is indicated for the treatment of Strabismus and Blepharospasm associated with dystonia, including benign essential blepharospasm or VII nerve disorders in patients 12 years of age and older.

Please see additional Indications, additional Limitations of Use, and additional Important Safety Information about BOTOX® on following pages. 3


Add a Prescriber (continued)

Add an additional prescriber

- Click the **Save and Add Additional Prescriber** button
- After clicking **Save and Add Additional Prescriber**, enter a valid NPI number in the Search NPI field
- Click **Search**
 - Provider's name will automatically populate in the gray field based on the NPI number
- Confirm prescriber's information
- Add an Alias or Individual Tax ID if necessary

Note: The Alias field lets you add a preferred name to the prescriber other than the one returned from the NPI registry. If an alias is not entered, prescriber name will default to the name from the NPI registry.

- Click the **Save and Continue** button if you do not wish to add any more prescribers
- Click **Save and Add Additional Prescriber** if you would like to add another prescriber



Indications (continued)

Primary Axillary Hyperhidrosis

BOTOX® is indicated for the treatment of severe primary axillary hyperhidrosis that is inadequately managed with topical agents.

Limitations of Use

The safety and effectiveness of BOTOX® for hyperhidrosis in other body areas have not been established. Weakness of hand muscles and blepharoptosis may occur in patients who receive BOTOX® for palmar hyperhidrosis and facial hyperhidrosis, respectively. Patients should be evaluated for potential causes of secondary hyperhidrosis (eg, hyperthyroidism) to avoid symptomatic treatment of hyperhidrosis without the diagnosis and/or treatment of the underlying disease.

Safety and effectiveness of BOTOX® have not been established for the treatment of axillary hyperhidrosis in pediatric patients under age 18.

IMPORTANT SAFETY INFORMATION (continued)

CONTRAINDICATIONS

BOTOX® is contraindicated in the presence of infection at the proposed injection site(s) and in patients who are hypersensitive to any botulinum toxin product or to any of the components in the formulation.

BOTOX® is contraindicated for intradetrusor injection in patients with a urinary tract infection, or in patients with urinary retention, or post-void residual (PVR) urine volume > 200 mL who are not routinely performing clean intermittent self-catheterization (CIC).

WARNINGS AND PRECAUTIONS

Spread of Toxin Effect

See Boxed Warning.

No definitive serious adverse event reports of distant spread of toxin effect associated with BOTOX® for Blepharospasm at the recommended dose (30 Units and below), severe primary axillary hyperhidrosis at the recommended dose (100 Units), Strabismus, or for Chronic Migraine at the labeled doses have been reported.


Please see additional Important Safety Information about BOTOX® on following pages.

Add an Additional Place of Service

- Review the Place of Service information that was previously input at the beginning of registration

Note: You will be able to make any necessary changes at the end of the registration process.

- Click **Save and Add Another Location** if you would like to add another location
 - Complete all required fields (Location, Phone Number, Place of Service, Street Address, City, State, Zip Code)
- Click **Save and Continue** if you do not want to add another location at this time



Note: User will be redirected to the Review Registration Summary page.

IMPORTANT SAFETY INFORMATION (continued) WARNINGS AND PRECAUTIONS (continued)

Lack of Interchangeability Between Botulinum Toxin Products

The potency Units of BOTOX[®] are specific to the preparation and assay method utilized. They are not interchangeable with other preparations of botulinum toxin products and, therefore, Units of biological activity of BOTOX[®] cannot be compared to nor converted into Units of any other botulinum toxin products assessed with any other specific assay method.

Serious Adverse Reactions With Unapproved Use

Serious adverse reactions, including excessive weakness, dysphagia, and aspiration pneumonia, with some adverse reactions associated with fatal outcomes, have been reported in patients who received BOTOX[®] injections for unapproved uses. In these cases, the adverse reactions were not necessarily related to distant spread of toxin, but may have resulted from the administration of BOTOX[®] to the site of injection and/or adjacent structures. In several of the cases, patients had preexisting dysphagia or other significant disabilities. There is insufficient information to identify factors associated with an increased risk for adverse reactions associated with the unapproved uses of BOTOX[®]. The safety and effectiveness of BOTOX[®] for unapproved uses have not been established.

Hypersensitivity Reactions

Serious and/or immediate hypersensitivity reactions have been reported. These reactions include anaphylaxis, serum sickness, urticaria, soft-tissue edema, and dyspnea. If such a reaction occurs, further injection of BOTOX[®] should be discontinued and appropriate medical therapy immediately instituted. One fatal case of anaphylaxis has been reported in which lidocaine was used as the diluent, and consequently, the causal agent cannot be reliably determined.

Increased Risk of Clinically Significant Effects With Preexisting Neuromuscular Disorders

Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis (ALS), or neuromuscular junction disorders (eg, myasthenia gravis or Lambert-Eaton syndrome) should be monitored when given botulinum toxin. Patients with known or unrecognized neuromuscular disorders or neuromuscular junction disorders may be at increased risk of clinically significant effects, including generalized muscle weakness, diplopia, ptosis, dysphonia, dysarthria, severe dysphagia, and respiratory compromise from therapeutic doses of BOTOX[®] (see *Warnings and Precautions*).

Dysphagia and Breathing Difficulties

Treatment with BOTOX[®] and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with preexisting swallowing or breathing difficulties may be more susceptible to these complications. In most cases, this is a consequence of weakening of muscles in the area of injection that are involved in breathing or oropharyngeal muscles that control swallowing or breathing (see *Boxed Warning*).

Pulmonary Effects of BOTOX[®] in Patients With Compromised Respiratory Status Treated for Spasticity or for Detrusor Overactivity Associated With a Neurologic Condition

Patients with compromised respiratory status treated with BOTOX[®] for spasticity or detrusor overactivity associated with a neurologic condition should be monitored closely.

Corneal Exposure and Ulceration in Patients Treated With BOTOX[®] for Blepharospasm

Reduced blinking from BOTOX[®] injection of the orbicularis muscle can lead to corneal exposure, persistent epithelial defect, and corneal ulceration, especially in patients with VII nerve disorders.

Please see additional Important Safety Information about BOTOX[®] on following pages.

Review Registration Summary

- Review all information to confirm
- Click the **pencil icon** in the upper right-hand corner to edit information
- Once practice information is confirmed, read and agree to the **Practice Attestation**
- Click the **Finish Registration** button

Note: User will be redirected to set up a BOTOX ONE® Account (Registration Complete) page.

Registration Complete

- Click the **Get Started** button to be redirected to the Home Dashboard

Note: A Welcome email will be sent to the inbox of the address used to register. The email will not be used for validation purposes.

BOTOX ONE® Registration Summary

Please review the information you provided below. If everything is correct, agree to the Practice Attestation and click Finish Registration.

Contact Details

First Name: John	Last Name: Doe	Title/Role: Healthcare Personnel
Email Address: johndoe@gmail.com	Phone: (888) 888-8888	Phone Extension: Fax:

Practice Details

Practice Name: John Doe	Place of Service: 11 - Provider's Office
Organization NPI: Street Address: 123 Any Street	Facility Tax ID: 123456789
Street Address 2: Floor/Suite:	City: Any City
State: California	ZIP Code: 99999
Phone: (888) 888-8888	Phone Extension: Fax:

Prescribers

First Name: SARRY	Last Name: AARONSON
Designation: OTHER	Prescriber Specialty: Psychologist - Prescribing (Medical)
NPI: 1451901787	Individual Tax ID:
Alias:	

Locations

Location Name: 123 Any Street	Phone: (888) 888-8888	Place of Service: 11 - Provider's Office
Street Address: 123 Any Street		
Street Address 2: Floor/Suite:	City: Any City	State: California
		ZIP Code: 99999
Fax:		

Preferences

Email Notification Preferences: None

Document Delivery Preferences:

Practice Attestation

BOTOX ONE® is provided as an information service only. While every attempt is made to provide up-to-date information, Allergan does not ensure the accuracy of the information provided and these results are not a guarantee of coverage. Since third-party reimbursement is affected by many factors, Allergan makes no representation or guarantee that a patient will be successful in obtaining insurance reimbursement or any other payments. Health plans, coverage criteria, and formularies are subject to change without notice. Check each patient's coverage with applicable insurers. Allergan does not endorse any individual plans. Decisions regarding medical necessity and documentation to support coverage of BOTOX® must be made by the provider/physician considering the clinical facts, circumstances, and applicable coverage rules. Coverage does not imply efficacy or safety. Please see full prescribing information, including boxed warning, at www.BOTOX.com.

I certify and agree with the above attestation

Back Finish Registration

IMPORTANT SAFETY INFORMATION (continued) WARNINGS AND PRECAUTIONS (continued)

Retrolbulbar Hemorrhages in Patients Treated With BOTOX® for Strabismus

During the administration of BOTOX® for the treatment of Strabismus, retrolbulbar hemorrhages sufficient to compromise retinal circulation have occurred. It is recommended that appropriate instruments to decompress the orbit be accessible.



Bronchitis and Upper Respiratory Tract Infections in Patients Treated for Spasticity

Bronchitis was reported more frequently as an adverse reaction in adult patients treated for upper limb spasticity with BOTOX® (3% at 251 Units to 360 Units total dose) compared to placebo (1%). In adult patients with reduced lung function treated for upper limb spasticity, upper respiratory tract infections were also reported more frequently as adverse reactions in patients treated with BOTOX® (11% at 360 Units total dose; 8% at 240 Units total dose) compared to placebo (6%). In adult patients treated for lower limb spasticity, upper respiratory tract infections were reported more frequently as an adverse reaction in patients treated with BOTOX® (2% at 300 Units to 400 Units total dose) compared to placebo (1%). In pediatric patients treated for upper limb spasticity, upper respiratory tract infections were reported more frequently as an adverse reaction in patients treated with BOTOX® (17% at 6 Units/kg and 10% at 3 Units/kg) compared to placebo (9%). In pediatric patients treated for lower limb spasticity, upper respiratory tract infection was not reported with an incidence greater than placebo.

Please see additional Important Safety Information about BOTOX® on following pages.

Need Help With Username or Password?

If you're having trouble logging in and need help with your username or password, select the link "Forgot Password/Can't Log In" located directly below the password field of the homepage. Or [click here](#) to be taken to the Login Help page.



IMPORTANT SAFETY INFORMATION (continued) WARNINGS AND PRECAUTIONS (continued)

Autonomic Dysreflexia in Patients Treated for Detrusor Overactivity Associated With a Neurologic Condition

Autonomic dysreflexia associated with intradetrusor injections of BOTOX[®] could occur in patients treated for detrusor overactivity associated with a neurologic condition and may require prompt medical therapy. In clinical trials, the incidence of autonomic dysreflexia was greater in adult patients treated with BOTOX[®] 200 Units compared with placebo (1.5% vs 0.4%, respectively).

Urinary Tract Infections in Patients With Overactive Bladder

BOTOX[®] increases the incidence of urinary tract infection. Clinical trials for overactive bladder excluded patients with more than 2 UTIs in the past 6 months and those taking antibiotics chronically due to recurrent UTIs. Use of BOTOX[®] for the treatment of overactive bladder in such patients and in patients with multiple recurrent UTIs during treatment should only be considered when the benefit is likely to outweigh the potential risk.

Urinary Retention in Adults Treated for Bladder Dysfunction

Due to the risk of urinary retention, treat only patients who are willing and able to initiate catheterization post treatment, if required, for urinary retention.

In patients who are not catheterizing, post-void residual (PVR) urine volume should be assessed within 2 weeks post treatment and periodically as medically appropriate up to 12 weeks, particularly in patients with multiple sclerosis or diabetes mellitus. Depending on patient symptoms, institute catheterization if PVR urine volume exceeds 200 mL and continue until PVR falls below 200 mL. Instruct patients to contact their physician if they experience difficulty in voiding as catheterization may be required.

Overactive Bladder

In clinical trials, 6.5% of patients (36/552) initiated clean intermittent catheterization for urinary retention following treatment with BOTOX[®] 100 Units, as compared to 0.4% of patients (2/542) treated with placebo. The median duration of catheterization for patients treated with BOTOX[®] 100 Units was 63 days (minimum 1 day to maximum 214 days), as compared to a median duration of 11 days (minimum 3 days to maximum 18 days) for patients receiving placebo.

Patients with diabetes mellitus treated with BOTOX[®] were more likely to develop urinary retention than nondiabetics. In clinical trials, 12.3% of patients (10/81) with diabetes developed urinary retention following treatment with BOTOX[®] 100 Units vs 0% of patients (0/69) treated with placebo. In patients without diabetes, 6.3% of patients (33/526) developed urinary retention following treatment with BOTOX[®] 100 Units vs 0.6% of patients (3/516) treated with placebo.

Adult Detrusor Overactivity Associated With a Neurologic Condition

In clinical trials, 30.6% of adult patients (33/108) who were not using clean intermittent catheterization (CIC) prior to injection required catheterization for urinary retention following treatment with BOTOX[®] 200 Units as compared to 6.7% of patients (7/104) treated with placebo. The median duration of postinjection catheterization for these patients treated with BOTOX[®] 200 Units (n = 33) was 289 days (minimum 1 day to maximum 530 days,) as compared to a median duration of 358 days (minimum 2 days to maximum 379 days) for patients receiving placebo (n = 7).

Among adult patients not using CIC at baseline, those with multiple sclerosis were more likely to require CIC post injection than those with spinal cord injury.

Please see additional Important Safety Information about BOTOX[®] on following page.

IMPORTANT SAFETY INFORMATION (continued)

WARNINGS AND PRECAUTIONS (continued)

Human Albumin and Transmission of Viral Diseases

This product contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD). There is a theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD), but if that risk actually exists, the risk of transmission would also be considered extremely remote. No cases of transmission of viral diseases, CJD, or vCJD have ever been identified for licensed albumin or albumin contained in other licensed products.

ADVERSE REACTIONS

Adverse reactions to BOTOX® for injection are discussed in greater detail in the following sections: *Boxed Warning*, *Contraindications*, and *Warnings and Precautions*.

Overactive Bladder

The most frequently reported adverse reactions for overactive bladder occurring within 12 weeks of injection include urinary tract infection (BOTOX® 18%, placebo 6%); dysuria (BOTOX® 9%, placebo 7%); urinary retention (BOTOX® 6%, placebo 0%); bacteriuria (BOTOX® 4%, placebo 2%); and residual urine volume (BOTOX® 3%, placebo 0%).

A higher incidence of urinary tract infection was observed in patients with diabetes mellitus treated with BOTOX® 100 Units and placebo than nondiabetics.

The incidence of UTI increased in patients who experienced a maximum post-void residual (PVR) urine volume \geq 200 mL following BOTOX® injection compared to those with a maximum PVR $<$ 200 mL following BOTOX® injection, 44% vs 23%, respectively.

Adult Detrusor Overactivity Associated With a Neurologic Condition

The most frequently reported adverse reactions within 12 weeks of BOTOX® injection for detrusor overactivity associated with a neurologic condition include urinary tract infection (BOTOX® 24%, placebo 17%); urinary retention (BOTOX® 17%, placebo 3%); and hematuria (BOTOX® 4%, placebo 3%).

The following adverse event rates were reported at any time following initial injection and prior to reinjection or study exit (median duration of 44 weeks of exposure): urinary tract infections (49%), urinary retention (17%), constipation (4%), muscular weakness (4%), dysuria (4%), fall (3%), gait disturbance (3%), and muscle spasm (2%).

Pediatric Detrusor Overactivity Associated With a Neurologic Condition

The most frequently reported adverse reactions during the 12 weeks following BOTOX® injection of 200 Units for pediatric detrusor overactivity associated with a neurologic condition include bacteriuria (20%), urinary tract infection (7%), leukocyturia (7%), and hematuria (3%).

The most common adverse reactions in patients who received BOTOX® 6 Units/kg and less than a total dose of 200 Units were urinary tract infection (UTI), bacteriuria, and hematuria.

These patients were not adequately managed with at least one anticholinergic agent and were using clean intermittent catheterization at baseline.

Chronic Migraine

The most frequently reported adverse reactions following injection of BOTOX® for Chronic Migraine include neck pain (9%), headache (5%), eyelid ptosis (4%), migraine (4%), muscular weakness (4%), musculoskeletal stiffness (4%), bronchitis (3%), injection-site pain (3%), musculoskeletal pain (3%), myalgia (3%), facial paresis (2%), hypertension (2%), and muscle spasms (2%).

Adult Upper Limb Spasticity

The most frequently reported adverse reactions following injection of BOTOX® for upper limb spasticity include pain in extremity, muscular weakness, fatigue, nausea, and bronchitis.

Adult Lower Limb Spasticity

The most frequently reported adverse reactions following injection of BOTOX® for lower limb spasticity include arthralgia, back pain, myalgia, upper respiratory tract infection, and injection-site pain.

Pediatric Upper Limb Spasticity

The most frequently reported adverse reactions following injection of BOTOX® in pediatric upper limb spasticity include upper respiratory tract infection (includes upper respiratory tract infection and viral upper respiratory tract infection), injection-site pain, nausea, constipation, rhinorrhea, nasal congestion, and seizure (includes seizure and partial seizure).

Pediatric Lower Limb Spasticity

The most frequently reported adverse reactions following injection of BOTOX® in pediatric lower limb spasticity include injection-site erythema, injection-site pain, oropharyngeal pain, ligament sprain, skin abrasion, and decreased appetite.

Cervical Dystonia

The most frequently reported adverse reactions following injection of BOTOX® for Cervical Dystonia include dysphagia (19%), upper respiratory infection (12%), neck pain (11%), and headache (11%).

Blepharospasm

The most frequently reported adverse reactions following injection of BOTOX® for Blepharospasm include ptosis (21%), superficial punctate keratitis (6%), and eye dryness (6%).

Strabismus

The most frequently reported adverse events following injection of BOTOX® for Strabismus include ptosis (15.7%) and vertical deviation (16.9%).

Primary Axillary Hyperhidrosis

The most frequently reported adverse events (3%-10% of adult patients) following injection of BOTOX® for severe primary axillary hyperhidrosis in double-blind studies include injection-site pain and hemorrhage, nonaxillary sweating, infection, pharyngitis, flu syndrome, headache, fever, neck or back pain, pruritus, and anxiety.

Postmarketing Experience

Adverse reactions that have been identified during postapproval use of BOTOX® are discussed in greater detail in Postmarketing Experience (Section 6.3 of the Prescribing Information).

There have been spontaneous reports of death, sometimes associated with dysphagia, pneumonia, and/or other significant debility or anaphylaxis, after treatment with botulinum toxin. There have also been reports of adverse events involving the cardiovascular system, including arrhythmia and myocardial infarction, some with fatal outcomes. Some of these patients had risk factors, including cardiovascular disease. The exact relationship of these events to the botulinum toxin injection has not been established.

DRUG INTERACTIONS

Co-administration of BOTOX® and other agents interfering with neuromuscular transmission (eg, aminoglycosides, curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated. Use of anticholinergic drugs after administration of BOTOX® may potentiate systemic anticholinergic effects. The effect of administering different botulinum neurotoxin products at the same time or within several months of each other is unknown. Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin. Excessive weakness may also be exaggerated by administration of a muscle relaxant before or after administration of BOTOX®.

For more information on BOTOX®, please see the full [Prescribing Information](#), including [Boxed Warning](#) and [Medication Guide](#).